<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To clarify and quantify the effect of <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (TZDs; e.g., <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>) on the risk of <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e>, other selected <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, and overall <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, we performed a systematic review and meta-analysis of observational studies </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A PubMed/MEDLINE search was conducted for studies published in English up to June 30, 2012 </plain></SENT>
<SENT sid="2" pm="."><plain>Random-effect models were fitted to estimate summary relative risks (RR) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Seventeen studies satisfying inclusion criteria (3 case-control studies and 14 cohort studies) were considered </plain></SENT>
<SENT sid="4" pm="."><plain>Use of TZDs was not associated to the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> overall (summary RR: 0.96; 95% confidence interval [CI]: 0.91-1.01) </plain></SENT>
<SENT sid="5" pm="."><plain>A modest excess risk of <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> was reported in <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (RR: 1.20; 95% CI: 1.07-1.34 from six studies) but not in <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (RR: 1.08; 95% CI: 0.95-1.23 from three studies) users </plain></SENT>
<SENT sid="6" pm="."><plain>The RRs of <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> were higher for longer duration (RR: 1.42 for &gt;2 years) and higher cumulative dose of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (RR: 1.64 for &gt;28,000 mg) </plain></SENT>
<SENT sid="7" pm="."><plain>Inverse relations were observed with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (RR: 0.93; 95% CI: 0.90-0.97 from six cohort studies) and <z:hpo ids='HP_0002896'>liver cancer</z:hpo> (RR: 0.65; 95% CI: 0.48-0.89 from four studies), whereas there was no association with pancreatic, lung, breast, and <z:hpo ids='HP_0012125'>prostate cancers</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Adequate evidence excludes an overall excess <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk in TZD users within a few years after starting treatment </plain></SENT>
<SENT sid="9" pm="."><plain>However, there is a modest excess risk of <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e>, particularly with reference to <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Assuming that this association is real, the potential implications on the risk-benefit analysis of TZD use should be evaluated </plain></SENT>
</text></document>